

OCT 27 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jackson, et al.
 Application No.: 10/828,395
 Filed: 4/19/2004
 Title: Method for Treatment of Angiogenic Disorders
 Attorney Docket No.: UBC.P-032
 Customer No.: 021121

Group Art Unit: 1635
 Examiner: Tracy Ann Vivlemore
 Confirmation No: 5836

Commissioner for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the Office Action of October 17, 2005, Applicants hereby elect group I, that is antisense oligonucleotide therapeutics, and as a single nucleotide structure Seq. ID No. 5, which has the sequence CAGCAGCAGAGTCTTCATCAT.

This election is made without traverse.

Respectfully submitted,

Marina T. Larson
 Marina T. Larson Ph.D.
 PTO Reg. No. 32,038
 Attorney for Applicant
 (970) 468-6600

I hereby certify that this paper and any attachments named herein are transmitted to the United States Patent and Trademark Office, Fax number: 571-273-8300 on October 27, 2005.

Marina T. Larson
 Marina T. Larson, PTO Reg. No. 32,038

October 27, 2005
 Date of Signature